Company news

CytoSorbents Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CytoSorbents to Report First Quarter 2023 Operating and Financial Results

April 25, 2023

CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled

April 19, 2023

CytoSorbents Announces Board Chairman Al W. Kraus To Retire

April 18, 2023

Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation

March 28, 2023

CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)

March 21, 2023

CytoSorbents Comments on Bank Exposure and Diversified Cash Position

March 13, 2023

CytoSorbents Reports Fourth Quarter and Full Year 2022 Results

March 8, 2023

CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference

February 26, 2023

CytoSorbents to Report Fiscal 2022 Operating and Financial Results

February 23, 2023

CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue

January 30, 2023

CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial

January 22, 2023

CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs

January 16, 2023

CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement

December 28, 2022

CytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without Modifications

December 20, 2022

CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled

November 13, 2022

CytoSorbents Reports Third Quarter 2022 Financial and Operational Results

November 2, 2022

CytoSorbents to Report Third Quarter 2022 Operating and Financial Results

October 26, 2022

CytoSorbents Reports New Cardiac Surgery Data with CytoSorb at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting

October 11, 2022

CytoSorbents Announces Pending Retirement of Chief Financial Officer Kathleen P. Bloch

October 6, 2022

CytoSorbents Awarded an Approximately $4.3M Contract by the U.S. Department of Defense to Develop HemoDefend-BGA™ for Freeze-Dried Universal Plasma

October 5, 2022

CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey

September 26, 2022

CytoSorbents Reports Second Quarter 2022 Financial and Operational Results

August 1, 2022

CytoSorbents to Hold 2022 Annual Meeting of Stockholders Virtually

June 1, 2022

CytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 Countries

May 31, 2022

CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook

May 2, 2022

CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany

May 1, 2022

First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb™-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery

April 28, 2022

CytoSorbents Highlights the Strategy of "Enhanced Lung Rest" Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress

April 27, 2022

CytoSorbents to Report First Quarter 2022 Operating and Financial Results

April 18, 2022

CytoSorbents To Expand Direct Sales of CytoSorb® to the United Kingdom, the Sixth Largest Medical Device Market in the World

April 13, 2022

CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors

April 4, 2022

CytoSorbents Reports Fourth Quarter and Full Year 2021 Results and Provides 2022 Outlook

March 7, 2022

CytoSorbents Announces Participation in Two Upcoming Virtual Investor Conferences

February 2, 2022

CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

January 17, 2022

CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular

December 20, 2021

CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

December 19, 2021

CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results

November 3, 2021

First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery

October 13, 2021

CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery

October 11, 2021

CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance

October 11, 2021

CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference

October 6, 2021

CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery

September 9, 2021

CytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

September 7, 2021

Topline Results from CytoSorbents' U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

August 31, 2021

CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress

August 29, 2021

Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery

August 11, 2021

CytoSorbents Reports Second Quarter 2021 Financial and Operational Results

August 2, 2021

CytoSorbents Completes its Mission 100,000 International Fundraising Campaign to Fight the Spread of COVID-19 for Global Humanitarian Organization, CARE

July 29, 2021

CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery

July 5, 2021

CytoSorbents Appoints Terri Anne Powers, IRC as Vice President of Investor Relations and Corporate Communications

May 31, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 78 decks. Every deck is listed under its year.